| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | 0.1 | 0.04 |
| mRNA | B02 | CTRPv2 | pan-cancer | AAC | -0.085 | 0.04 |
| mRNA | LY-2157299 | CTRPv2 | pan-cancer | AAC | 0.16 | 0.04 |
| mRNA | MI-2 | CTRPv2 | pan-cancer | AAC | -0.13 | 0.04 |
| mRNA | XMD15-27 | GDSC1000 | pan-cancer | AAC | 0.072 | 0.04 |
| mRNA | ZM-447439 | GDSC1000 | pan-cancer | AAC | 0.075 | 0.04 |
| mRNA | pifithrin-alpha | CTRPv2 | pan-cancer | AAC | 0.085 | 0.04 |
| mRNA | JQ-1:MK-0752 (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.077 | 0.04 |
| mRNA | PD-0325901 | gCSI | pan-cancer | AAC | 0.11 | 0.04 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | -0.1 | 0.04 |